BioMaxima S.A. (WSE:BMX)
Poland
· Delayed Price · Currency is PLN 14.30
+0.90 (6.72%)
Jun 27, 2025, 5:00 PM CET
BioMaxima Revenue
BioMaxima had revenue of 15.28M PLN in the quarter ending March 31, 2025, with 32.51% growth. This brings the company's revenue in the last twelve months to 56.60M, up 19.81% year-over-year. In the year 2024, BioMaxima had annual revenue of 52.85M with 12.96% growth.
Revenue (ttm)
56.60M
Revenue Growth
+19.81%
P/S Ratio
1.02
Revenue / Employee
449.21K
Employees
126
Market Cap
57.66M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 52.85M | 6.07M | 12.96% |
| Dec 31, 2023 | 46.79M | -97.08M | -67.48% |
| Dec 31, 2022 | 143.87M | 64.78M | 81.91% |
| Dec 31, 2021 | 79.09M | 17.81M | 29.06% |
| Dec 31, 2020 | 61.28M | 30.67M | 100.19% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| NEUCA | 12.82B |
| Synektik Spólka Akcyjna | 592.94M |
| Voxel | 556.98M |
| Celon Pharma | 215.11M |
| Ryvu Therapeutics | 97.57M |
| Centrum Medyczne ENEL-MED | 762.83M |
| Selvita | 359.79M |
| EMC Instytut Medyczny | 836.81M |